Company Profile

Tetragenetics Inc
Profile last edited on: 2/3/22      CAGE: 39AP0      UEI: E4V5EMGNKBY5

Business Identifier: Novel antibody therapeutics for ion-channel mediated disorders: expression of ion channel drug targets
Year Founded
2004
First Award
2005
Latest Award
2017
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

91 Mystic Street
Arllngton, MA 02474
   (617) 500-7471
   info@tetragenetics.com
   www.tetragenetics.com
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

TetraGenetics is had been a drug discovery company using proprietary technology (TetraExpress™) to discover large molecule drugs targeting ion channel membrane proteins associated with many human diseases. Supporting those seeking a cost-effective alternative platform technology for the production of genetically engineered proteins, in September 2021, TertraGenetics was acquired AbCellera whereby to enhancing the latter's capabilities to generate antibodies against high-value targets Having ties to Cornell with facilities in Ithaca NY and in Arlington, MA, Tetragenetic's drug discovery focus organized around discovery and development of first-in-class biologic medicines for autoimmune diseases, oncology and pain. The company" drug discovery platform (TetraExpress™) identified antibodies targeting ion channels and other transmembrane proteins. TetraGenetics had been actively building a proprietary drug pipeline and working collaboratively with major biotech companies for antibody drug discovery. Structured to address the needs of those seeking a cost-effective alternative platform technology for the production of genetically engineered proteins, the firm's technology is particularly well suited to the production of eucaryotic membrane and secretory proteins that are difficult to express in conventional systems. Such proteins include vaccine antigens, monoclonal antibodies, and a variety of therapeutic proteins for the treatment and prevention of human and animal disease. The firm's bio-pharmaceutical platform is designed to develop novel therapeutics for autoimmune diseases. The company's platform develops proprietary technology that helps in the rapid production of properly folded and functional ion channel proteins in membrane preparations and in purified form for use in antibody discovery and small molecule screening programs, enabling physicians to access treatments for ion channel related autoimmune diseases and pain manageme

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
20-24
Revenue Range
2M-2.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
---
IP Holdings
10-14

Awards Distribution by Agency

Key People / Management

  Marco Cacciuttolo -- President

  Doug Kahn -- CEO and Chairman

  Yelena Bisharyan -- Director of External Alliances

  Theodore G Clark -- CSO

  Margaret Coffey

  Paul Colussi -- Vice President, Research

  William Gordon III -- former President & Founder

  Kevin OBrien -- Chief Financial Officer

  Ashot Papoyan

  John Reilly -- Former Director Business Development